We, the concerned stakeholders of the pharmaceutical industry, call upon Uppsala Monitoring Centre (UMC) to make their WHODrug subscription model cognizant of the size and revenue of companies acquiring licenses. We believe that a fair pricing structure should be implemented to ensure equitable access to this vital resource.

WHODrug is an essential database used by pharmaceutical companies worldwide for drug safety monitoring and regulatory compliance. It provides standardized coding for drugs, enabling efficient analysis and reporting. However, the current subscription model employed by UMC fails to consider the financial capabilities of different organizations seeking access.

It is evident that smaller companies with limited resources face significant challenges in obtaining a WHODrug license due to exorbitant costs. This creates an unfair advantage for larger corporations who can easily afford these subscriptions without compromising their budgets or hindering research and development efforts.

According to industry reports from reputable sources such as Pharma Intelligence and EvaluatePharma, small- to medium-sized enterprises (SMEs) play a crucial role in driving innovation within the pharmaceutical sector. SMEs contribute significantly to drug discovery, development, and market competition while fostering economic growth. However, their potential impact is hindered when they are unable to access critical tools like WHODrug due to prohibitive pricing structures.

By implementing a tiered pricing system based on company size or revenue brackets, UMC can ensure fair access while still maintaining sustainable funding for its operations. This approach has been successfully adopted by various organizations across different industries as it promotes inclusivity without jeopardizing financial stability.

UMC's mission revolves around improving global health through pharmacovigilance activities. By making WHODrug more accessible through fair pricing practices aligned with company size and revenue levels, UMC would enhance its ability to fulfill this mission effectively.

We urge UMC management and relevant stakeholders to consider the following actions:

1. Conduct a comprehensive review of the current WHODrug subscription model, taking into account the financial capabilities of different organizations.
2. Collaborate with industry experts, regulatory bodies, and pharmaceutical associations to develop a tiered pricing structure that ensures fair access for all stakeholders.
3. Regularly reassess and adjust pricing tiers based on market dynamics and feedback from users to maintain fairness and sustainability.

Together, let us work towards a more equitable pharmaceutical landscape where companies of all sizes can access essential resources like WHODrug without undue financial burden. Sign this petition today to support fair pricing for UMC's WHODrug subscription model!

[Sources: Pharma Intelligence, EvaluatePharma]